FDA Antioxidants Claim Review Improperly Focused On Prevention - Lawsuit
This article was originally published in The Tan Sheet
Executive Summary
FDA inappropriately focused on cancer-prevention evidence in denying a proposed dietary supplement health claim for antioxidant vitamins and cancer risk reduction, supplement firms say in a lawsuit filed against the agency July 16.
You may also be interested in...
Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought
No particular dose of phosphatidylserine works better at reducing the severity of cognitive dysfunction and the risk of dementia, according to a health claim petition filed with FDA April 19
Antioxidants/Cancer Health Claim Contradicted By ATBC Study - FDA
Analyses from the 1994 Alpha-Tocopherol, Beta Carotene intervention trial raise "serious questions" about vitamin E's role in modifying cancer risk, FDA's Center for Food Safety & Applied Nutrition concludes May 4 in rejecting an antioxidant vitamins/cancer health claim.
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.